NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Zentalis reported third quarter 2022 financial results and provided operational updates.
Zentalis Pharmaceuticals reported a cash balance of $422 million as of September 30, 2022, with a projected cash runway into 2025. The company is advancing its clinical strategy for ZN-c3, including dose optimization and expansion into Cyclin E driven high-grade serous ovarian cancer. Collaborations with Pfizer and GSK are ongoing to explore ZN-c3 in combination therapies.
- Advanced clinical strategy for ZN-c3 with three-pronged development plan.
- Identified Cyclin E driven high-grade serous ovarian cancer patients as initial expansion population for ZN-c3 biomarker monotherapy trial.
- Announced first ZN-c3 clinical development collaboration with Pfizer BRAF-mutant mCRC; Expanded ZN-c3 clinical development collaboration with GSK in PARP resistant ovarian cancer.
- Declared BCL-xL protein degrader candidate and initiated IND-enabling studies.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$0
Forward guidance
Zentalis believes that its existing cash, cash equivalents and marketable securities as of September 30, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements into the first quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-1.7%
Avg return
Earnings day
-2.2%
Avg return
5 days after
+2.4%
Avg return
30 days after
58%
14 / 24 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -1.7% | — | |
| Q4 2025 | +3.1% | -3.7% | +49.1% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro